• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Has Breast Density Legislation Had Any Impact on Breast Cancer Diagnosis? 

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • 43 % of women have dense breasts which confers increased risk for breast cancer and reduces screening performance of mammography  
  • Supplemental screening with ultrasound or MRI has poor predictive value 
  • USPSTF (2016) recommends against supplemental screening due to lack of evidence of clinical benefit (decreased morbidity or mortality)  
  • 28 states have mandated physicians to inform patients of a finding of dense breasts 
    • Some states require patients be informed of option of potential benefit of supplemental screening 
    • Some states require private insurers to cover costs of supplemental screening  
  • Richman et al. (Journal of General Internal Medicine, 2017) evaluated impact of these laws on breast cancer outcomes based on changes in breast cancer stage at diagnosis after enactment of breast density notification legislation 

METHODS: 

  • Population cohort study  
    • Compared Connecticut, the first state to enact notification legislation, to states without such legislation to determine differences in stage of breast cancer at detection 
    • Evaluated changes in stage-specific incidence pre and post legislation to look for a reduction in late stage breast cancers  
    • Data was collected from the Surveillance, Epidemiology, and End Results (SEER) registry 

RESULTS: 

  • Final analysis included 466,930 women with a breast cancer diagnosis 
    • 25,592 lived in Connecticut  
  • Legislation was associated with 
    • 1.38-percentage-point increase in proportion of women with localized invasive cancer at the time of diagnosis 
    • 1.12-percent-point decline in proportion of women with ductal carcinoma in situ at diagnosis 
  • Legislation was not associated with a change in the proportion of women in Connecticut versus control states with regional-stage or metastatic disease 

CONCLUSION: 

  • Whether this increase in localized breast cancer diagnoses is reflective of correct early detection or overdiagnosis remains unclear 
    • Researchers looked at the data by county to see if there was a relationship between increased early detection and decreased metastatic disease and could find no such association, suggesting these additional cases may be overdiagnosis  
    • However, may be underpowered and 4 year follow up may be insufficient to draw conclusions of benefit vs overdiagnosis  
  • Legislation was not associated with a change in any other regional or metastatic diagnosis 
  • Further study required to determine if there is any benefit to notification and supplemental screening for dense breasts  

Learn More – Primary Sources:  

Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry 

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Mammography Guidelines for Average-Risk Women
BI-RADS: Standardizing Breast Imaging and Reporting 
Office Evaluation of Breast Disorders

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site